Titanovo Logo
Back to Cell Types

SK-MEL-24Homo sapiens (Human)Cancer cell line

Also known as: AQ-Mel, SKMel24, SKMEL24, SK-Mel24, SK-MEL24, SKMEL-24, SK Mel 24, Sk-Mel-24

🤖 AI SummaryBased on 13 publications

Quick Overview

Human melanoma cell line with BRAF V600E mutation, used in cancer research.

Detailed Summary

SK-MEL-24 is a human melanoma cell line derived from a metastatic lesion. It harbors the BRAF V600E mutation, which is a common driver mutation in melanoma. This cell line is frequently used in research to study the effects of BRAF and MEK inhibitors, as well as the mechanisms of resistance to these therapies. The BRAF V600E mutation leads to constitutive activation of the MAPK/ERK pathway, making SK-MEL-24 a valuable model for investigating targeted therapies. Additionally, SK-MEL-24 has been utilized in studies examining the interplay between BRAF mutations and other genetic alterations, such as PTEN and RB1 loss, which can influence therapeutic response and resistance. The cell line's characteristics make it a key tool for understanding melanoma biology and developing effective treatment strategies.

Research Applications

BRAF V600E mutation studiesMEK inhibitor sensitivityResistance mechanisms to targeted therapiesInterplay between BRAF and PTEN/RB1 mutations

Key Characteristics

BRAF V600E mutationMAPK/ERK pathway activationSensitivity to BRAF and MEK inhibitorsRelevance to melanoma therapy research
Generated on 6/15/2025

Basic Information

Database IDCVCL_0599
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age67
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseMelanoma
LineageSkin
SubtypeMelanoma
OncoTree CodeMEL

DepMap Information

Source TypeATCC
Source IDACH-000822_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationNone reportedTP53---PubMed=19787792
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleBRAFp.Val600Glu (c.1799T>A)Unspecified-PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11
D13S317
12,13
D16S539
9,12
D18S51
16
D19S433
13,14
D21S11
29,31.2
D2S1338
23
D3S1358
15
D5S818
9,13
D7S820
9,12
D8S1179
14,15
FGA
22,23
Penta D
9
Penta E
11,12
TH01
6,9
TPOX
11
vWA
15
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Petricoin E.F. 3rd, Gioeli D., Weber M.J.

Oncotarget 7:2734-2753(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma.

Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.

PLoS ONE 10:E0138210-E0138210(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Rosen N., Solit D.B.

Cancer Res. 74:2340-2350(2014).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.

Wolchok J.D., Houghton A.N., Solit D.B.

Oncogene 31:446-457(2012).

DOIPubMedPMC

Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.

Brautigan D.L., Slingluff C.L. Jr.

Melanoma Res. 21:274-284(2011).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

Sharpless N.E.

Cancer Res. 67:1502-1512(2007).

DOIPubMed

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines.

Brinker M.G.L., Ruiters M.H.J., de Leij L.F.M.H., Buys C.H.C.M.

Int. J. Cancer 85:871-876(2000).

DOIPubMed

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

PubMed

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

J. Natl. Cancer Inst. 66:1003-1012(1981).

DOIPubMed

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

DOIPubMed

Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Old L.J.

Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).

DOIPubMedPMC

Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.

Shiku H., Takahashi T., Oettgen H.F., Old L.J.

J. Exp. Med. 144:873-881(1976).

DOIPubMedPMC

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

DOIPubMed

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Fogh J., Fogh J.M., Orfeo T.

J. Natl. Cancer Inst. 59:221-226(1977).

DOIPubMed

Malignant melanoma. Current status of the search for melanoma-specific antigens.

Houghton A.N., Oettgen H.F., Old L.J.

(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981).

DOI

Web Resources

mskcc.orgtcpaportal.org